After Demonstrating Its Safety and Efficacy: Can Novavax Rise To The Manufacturing Challenge?

Novavax (NASDAQ:NVAX) published results of its U.S. phase 3 trials for its Covid-19 vaccine in mid-June, noting that the shot was over 90% effective overall and 100% effective against moderate and severe disease, roughly in line with Covid vaccine leaders such as Pfizer and Moderna.

Although the shot is likely to hit the market only around Q4, almost ten months behind market leaders, considering that Emergency Use Authorizations are likely to be filed in the U.S., U.K., and Europe by the end of Q3, the emergence of concerning new coronavirus variants and a relatively slow pace of vaccination outside the U.S. likely mean that demand for Novavax’s shot will remain strong.

With questions regarding the efficacy and potential demand largely out of the way, the focus will turn to the ability of Novavax to produce and supply its vaccine at scale. The 34-year-old clinical-stage biotech has not produced a commercial product to date.

While Novavax has its own production facilities in the Czech Republic and Sweden, it will largely count on partnerships with contract manufacturing organizations around the world to produce a bulk of its vaccines and the antigens and adjuvants that go into them.

Novavax expects its total vaccine capacity to stand at about 100 million doses per month by the end of Q3 2021, scaling this up to approximately 150 million doses per month by the end of Q4. Of this, about one billion annualized doses will be manufactured by India’s Serum Institute, the world’s largest vaccine producer by volume.

Other licensed manufacturers of the shot include Japan’s Takeda Pharmaceutical and South Korea’s SK bioscience. However, these production targets might be somewhat optimistic.

How can any Covid 'vaccine' claim to have demonstrated it's Safety and Efficacy in miniature trials run by the pharma companies themselves?!

My notes on Dr. John Campbell's video "TUESDAY UPDATE" in which he reviews Novavax and a small Ivermectin study in Israel.
youtube.com ^ | Jun 15, 2021 | Dr. John Campbell and vanity

Posted on 6/16/2021, 2:03:15 AM by ransomnote

Dr. Campbell notes that he's reading from a press release and the vaccine research has not been peer reviewed yet.

ransomnote: I was wondering why there were so many news articles for Novavax all dated 6/14. Almost like press releases = free advertising from MSM. I saw elsewhere that Novavax development was also supported by the Bill & Melinda Gates foundation, among others.

How Novavax works:

DNA designed to make the spike proteins is put into another virus and that virus is put into moth cells. The DNA instructs the moth cells to mass produce the spike proteins, then the spike proteins are harvested (purified) from the moth cells.

The spike cells stick together and have the antigenic properties of the Sars 2 Covid virus, without the actual presence of the Covid virus.

ransomnote: Covid spike proteins are causing harm in other vaccines. Inventor Of mRNA Vaccine Technology: Spike Protein Is Dangerous, Its Cytotoxic. The FDA Was Warned About It Months Ago
First case of postmortem study in a patient vaccinated against SARS-CoV-2 [Spike Protein in every organ in his body!] or transcript:
Dr. Mercola Explains Dr. Bridle’s Bombshell Revelations Regarding Spike Proteins from Vaccines
Former Chief Science Officer at PFIZER VP: “THE THING TO BE TERRIFIED OF IS YOUR GOVERNMENT” (bitchute.com) Dr. Yeadon

Compared with the mRNA vaccines and DNA 'vaccines', which tell your own body cells to produce the spike protein, the Novavax is designed to directly inject the spike proteins into your body.

WHy does the NIH select companies like Moderna and Novavax which are going out of business to make these 'Covid shots'? Charity? Will some companies 'play ball' to get those billions if the alternative is the failure of the business?

The long shot [Novavax Covid Vaccine]
sciencemag.org ^ | 06 Nov 2020: | Meredith Wadman

Posted on 6/15/2021, 11:38:33 PM by ransomnote

SNIP

Eighteen months ago, a small vaccinemaker here called Novavax faced an existential threat: delisting by the NASDAQ stock index. On the heels of a second failed vaccine trial in less than 3 years, the firm's shares had plunged to less than $1 for 30 straight days, triggering a warning by NASDAQ. Frantic to conserve cash, the company sold its two Maryland manufacturing facilities, slicing its payroll by more than 100 employees. By January, it employed only 166 people.

“Good ideas. Bad management. … The company will probably die soon,” a former Novavax manager wrote on Glassdoor.com in October 2019.

What a difference a year—and a pandemic—make. Today, Novavax is slated to receive up to $2 billion from the U.S. government and a nonprofit organization to develop and manufacture a coronavirus vaccine.

SNIP

Novavax's vaccine is made of tiny particles studded with the coronavirus spike protein plus honeycomblike molecules, derived from plants, that stimulate the immune system.

Image of Novavax's tiny particles studded with coronavirus spike proteins

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.